News | February 16, 2024
Marksans Q3 FY24 revenue up 22% at Rs 586 Cr
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
Guaifenesin extended-release tablets help to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive
The inspection was conducted at its Goa, Vema manufacturing facility
Plans to double its manufacturing footprint to bolster the growth
A seasoned professional, he will lead the strategy and business operations of Cadila’s branded prescriptions pharma business
Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs
The company will manufacture the products at its US FDA approved oral dosage facility at Goa in India
Subscribe To Our Newsletter & Stay Updated
